News

10 02, 2017

Eos Biosciences will attend the 2017 Biotechnology Innovation Organization (BIO)

February 10th, 2017|

Eos Biosciences will attend the 2017 Biotechnology Innovation Organization (BIO) CEO & Investor Conference being held February 13-14, 2017, in New York.  Eos Biosciences’ Chief Executive Officer, Omar Haffar, Ph.D. and Chief Financial Officer, Thomas Plotts will attend the BIO CEO & Investor Conference.

1 06, 2016

Eos Biosciences will attend the 2016 Biotechnology Innovation Organization (BIO) International Convention

June 1st, 2016|

June 1, 2016 – Eos Biosciences will attend the 2016 Biotechnology Innovation Organization (BIO) International Convention being held June 6 - 9, 2016, in San Francisco. Eos Biosciences’ Chief Executive Officer, Omar Haffar, Ph.D. and Chief Financial Officer, Thomas Plotts will attend the BIO International Convention.

21 04, 2016

Eos Biosciences, Inc. recruited Thomas Plotts to join the company as its Chief Financial Officer

April 21st, 2016|

April 21, 2016 – Eos Biosciences, Inc. recruited Thomas Plotts to join the company as its Chief Financial Officer. Plotts previously served as Chief Financial Officer and Vice President, Finance at Los Angeles Biomedical Research Institute, a world-class independent biomedical research institute focused on the discover, causes and genetic underpinnings of rare, chronic and infectious diseases. [...]

29 12, 2015

Eos Biosciences, Inc. closed its Series A financing round in December, 2015, with follow-on participation from all of the investors in the company’s seed round.

December 29th, 2015|

4 01, 2015

Eos Biosciences, Inc. completed its seed financing round in January, 2015 and is now in the process of rounding out its Series A financing, already having secured follow-on participation from all of the investors in the company’s seed round.

January 4th, 2015|

Eos Biosciences, Inc. completed its seed financing round in January, 2015 and is now in the process of rounding out its Series A financing, already having secured follow-on participation from all of the investors in the company’s seed round.

5 05, 2014

Eos Biosciences, Inc. adds Peter Linsley, Ph.D. and Michael Kahn, Ph.D. to the company’s Science Advisory Board.

May 5th, 2014|

Eos Biosciences, Inc. adds Peter Linsley, Ph.D. and Michael Kahn, Ph.D. to the company’s Science Advisory Board. Dr. Linsley an expert in RNAi therapeutics, Oncology and Immunology is currently a Research Associate Member at the Benaroya Research Institute. Dr. Kahn has expertise in Oncology, Peptidomimetics and Molecular & Cell Biology and is currently Provost Professor [...]

26 12, 2013

Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement

December 26th, 2013|

Eos Biosciences, Inc. and Cedars-Sinai Medical Center sign a license agreement, providing Eos Biosciences with an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center. The agreement covers nanopartical technology patent rights for use in the prevention, treatment or diagnosis of diseases.